← Leaderboards
Jann N Sarkaria
Mayo Clinic Coll Of Medicine, Rochester
$30,462,841
Attributed
$33,944,126
Total exposure
32
Grants
24
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$50,447,097 · 33
FDA$1,298,525 · 1
By mechanism
R01$15,555,246 · 9
U54$13,833,893 · 6
U19$10,622,004 · 7
P50$3,409,760 · 3
U01$2,952,359 · 1
P30$2,108,094 · 2
Top collaborators
- Forest M White16 shared
- Ranjit Bindra7 shared
- Evanthia Galanis7 shared
- William F Elmquist6 shared
- Candece L Gladson5 shared
- Antonio M Omuro4 shared
- Louis James Maher2 shared
- Kyoji Tsuchikama1 shared
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Joon H Uhm$1,414,253
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorBrain NeoplasmsGlioblastomaResponseNovel TherapeuticsPharmaceutical PreparationsCollaborationsBrainBaseMalignant Neoplasm Of BrainRadiationSignal TransductionClinical TrialsXenograft ProcedureRadiation TherapyTemozolomideDrug DistributionIn VivoMolecularAnimalsChemotherapyScientistPharmacologyResistance
Grant awards (127)
Center of Innovation for Brain Tumor Therapeutics$1,203,578
U19 · FY2025 · CA · contact PI
Maximizing the efficacy of MDM2 inhibitor therapy for MDM2-amplified glioblastoma$660,920
R01 · FY2025 · CA · contact PI
Antibody Drug Conjugate Designs to Enhance the Therapeutic Window for Brain Tumors$652,751
R01 · FY2025 · NS · contact PI
Development of the brain penetrant ATM inhibitor WSD0628 in combination with radiation for recurrent high grade glioma$649,264
R01 · FY2025 · FD · contact PI
Core 1: Biospecimens Core$333,412
U54 · FY2025 · CA · contact PI
Therapy Evaluation Core$265,248
U19 · FY2025 · CA · contact PI
MDM2 inhibitor therapy for TP53 wild-type GBM$133,307
U19 · FY2025 · CA · contact PI
Administrative Core$121,053
U19 · FY2025 · CA · contact PI
Center of Innovation for Brain Tumor Therapeutics$1,861,663
U19 · FY2024 · CA · contact PI
Maximizing the efficacy of MDM2 inhibitor therapy for MDM2-amplified glioblastoma$458,021
R01 · FY2024 · CA · contact PI
Therapy Evaluation Core$419,141
U19 · FY2024 · CA · contact PI
In vivo SELEX strategies to identify potent aptamer-drug conjugates for glioblastoma$386,233
R61 · FY2024 · NS · contact PI
Core 1: Biospecimens Core$316,740
U54 · FY2024 · CA · contact PI
MDM2 inhibitor therapy for TP53 wild-type GBM$174,365
U19 · FY2024 · CA · contact PI
Administrative Core$168,181
U19 · FY2024 · CA · contact PI
Neuro-Oncology Program$80,872
P30 · FY2024 · CA · contact PI
Center of Innovation for Brain Tumor Therapeutics$1,999,213
U19 · FY2023 · CA · contact PI
Development of the brain penetrant ATM inhibitor WSD0628 in combination with radiation for recurrent high grade glioma$649,261
R01 · FY2023 · FD · contact PI
In vivo SELEX strategies to identify potent aptamer-drug conjugates for glioblastoma$414,690
R61 · FY2023 · NS · contact PI
Endocytic Trafficking of ADCs in GBM cancer stem-like cells$350,438
R01 · FY2023 · NS
Core 1: Biospecimens Core$348,162
U54 · FY2023 · CA · contact PI
Therapy Evaluation Core$339,198
U19 · FY2023 · CA · contact PI
MDM2 inhibitor therapy for TP53 wild-type GBM$245,952
U19 · FY2023 · CA · contact PI
Administrative Core$228,864
U19 · FY2023 · CA · contact PI
Neuro-Oncology Program$99,154
P30 · FY2023 · CA · contact PI
Center of Innovation for Brain Tumor Therapeutics$1,187,659
U19 · FY2022 · CA · contact PI
Pre-Clinical Novel Radiosensitizer Evaluation Program for Brain Tumors$552,341
U01 · FY2022 · CA · contact PI
Endocytic Trafficking of ADCs in GBM cancer stem-like cells$350,438
R01 · FY2022 · NS
MDM2 inhibitor therapy for TP53 wild-type GBM$155,170
U19 · FY2022 · CA · contact PI
Therapy Evaluation Core$155,094
U19 · FY2022 · CA · contact PI
Administrative Core$127,356
U19 · FY2022 · CA · contact PI
Neuro-Oncology Program$99,278
P30 · FY2022 · CA · contact PI
Center of Innovation for Brain Tumor Therapeutics - Diversity Supplement$61,986
U19 · FY2022 · CA · contact PI
Admin-Core-001$61,986
U19 · FY2022 · CA · contact PI
Center of Innovation for Brain Tumor Therapeutics$1,243,819
U19 · FY2021 · CA · contact PI
Pre-Clinical Novel Radiosensitizer Evaluation Program for Brain Tumors$593,139
U01 · FY2021 · CA · contact PI
Endocytic Trafficking of ADCs in GBM cancer stem-like cells$350,438
R01 · FY2021 · NS
Therapy Evaluation Core$175,318
U19 · FY2021 · CA · contact PI
MDM2 inhibitor therapy for TP53 wild-type GBM$172,801
U19 · FY2021 · CA · contact PI
Administrative Core$121,052
U19 · FY2021 · CA · contact PI
Neuro-Oncology Program$99,154
P30 · FY2021 · CA · contact PI
MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors$1,990,625
U54 · FY2020 · CA
Pre-Clinical Novel Radiosensitizer Evaluation Program for Brain Tumors$581,676
U01 · FY2020 · CA · contact PI
Endocytic Trafficking of ADCs in GBM cancer stem-like cells$353,412
R01 · FY2020 · NS
Core 2: Animal and Pharmacology$282,864
U54 · FY2020 · CA · contact PI
Trans Network Project$132,856
U54 · FY2020 · CA
Admin-Core-001$102,364
U54 · FY2020 · CA
Neuro-Oncology Program$101,598
P30 · FY2020 · CA · contact PI
Pre-Clinical Novel Radiosensitizer Evaluation Program for Brain Tumors$64,409
U01 · FY2020 · CA · contact PI
MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors$1,831,800
U54 · FY2019 · CA
Pre-Clinical Novel Radiosensitizer Evaluation Program for Brain Tumors$564,304
U01 · FY2019 · CA · contact PI
Endocytic Trafficking of ADCs in GBM cancer stem-like cells$357,223
R01 · FY2019 · NS
The Mayo GBM Xenograft National Resource$294,973
R24 · FY2019 · NS · contact PI
Core 2: Animal and Pharmacology$274,378
U54 · FY2019 · CA · contact PI
Trans Network Project$128,869
U54 · FY2019 · CA
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)$102,364
U54 · FY2019 · CA
Admin-Core-001$102,364
U54 · FY2019 · CA
Neuro-Oncology Program$82,581
P30 · FY2019 · CA · contact PI
MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors$2,046,454
U54 · FY2018 · CA
Pre-Clinical Novel Radiosensitizer Evaluation Program for Brain Tumors$596,490
U01 · FY2018 · CA · contact PI
The Mayo GBM Xenograft National Resource$381,112
R24 · FY2018 · NS · contact PI
Core 2: Animal and Pharmacology$306,530
U54 · FY2018 · CA · contact PI
Trans Network Project$143,971
U54 · FY2018 · CA
MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors$107,900
U54 · FY2018 · CA
Trans Network Project$15,414
U54 · FY2018 · CA
Core 2: Animal and Pharmacology$15,414
U54 · FY2018 · CA · contact PI
MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors$2,012,210
U54 · FY2017 · CA
(PQD3) Mechanisms of prolonged initial disease-free survival in glioblastoma$738,276
R01 · FY2017 · CA · contact PI
Mechanisms of acquired temozolomide resistance in glioblastoma multiforme$329,925
R01 · FY2017 · CA · contact PI
Core 2: Animal and Pharmacology$299,875
U54 · FY2017 · CA · contact PI
The Mayo GBM Xenograft National Resource$258,808
R24 · FY2017 · NS · contact PI
Trans Network Project$140,846
U54 · FY2017 · CA
MIT/Mayo Physical Sciences Center for Drug Distribution and Efficacy in Brain Tumors$2,152,225
U54 · FY2016 · CA
(PQD3) Mechanisms of prolonged initial disease-free survival in glioblastoma$738,276
R01 · FY2016 · CA · contact PI
Influence of Anti-Angiogenic Therapy on Drug Delivery to Brain Tumors$493,422
R01 · FY2016 · NS
Mechanisms of acquired temozolomide resistance in glioblastoma multiforme$329,925
R01 · FY2016 · CA · contact PI
Core 2: Animal and Pharmacology$300,543
U54 · FY2016 · CA · contact PI
supplement$213,699
U54 · FY2016 · CA
The Mayo GBM Xenograft National Resource$181,658
R24 · FY2016 · NS · contact PI
Trans Network Project$132,014
U54 · FY2016 · CA
(PQD3) Mechanisms of prolonged initial disease-free survival in glioblastoma$719,226
R01 · FY2015 · CA · contact PI
Influence of Anti-Angiogenic Therapy on Drug Delivery to Brain Tumors$493,574
R01 · FY2015 · NS
Animal Core$392,176
P50 · FY2015 · CA · contact PI
Mechanisms of acquired temozolomide resistance in glioblastoma multiforme$329,925
R01 · FY2015 · CA · contact PI
Influence of DNA repair on PARP Inhibitor efficacy In GBM$297,244
P50 · FY2015 · CA · contact PI
(PQD3) Mechanisms of prolonged initial disease-free survival in glioblastoma$669,147
R01 · FY2014 · CA · contact PI
Influence of Anti-Angiogenic Therapy on Drug Delivery to Brain Tumors$488,787
R01 · FY2014 · NS
Animal Core$346,563
P50 · FY2014 · CA · contact PI
Mechanisms of acquired temozolomide resistance in glioblastoma multiforme$320,027
R01 · FY2014 · CA · contact PI
Influence of DNA repair on PARP Inhibitor efficacy In GBM$276,757
P50 · FY2014 · CA · contact PI
Influence of Anti-Angiogenic Therapy on Drug Delivery to Brain Tumors$476,586
R01 · FY2013 · NS
Animal Core$403,110
P50 · FY2013 · CA · contact PI
Mechanisms of acquired temozolomide resistance in glioblastoma multiforme$329,925
R01 · FY2013 · CA · contact PI
Overcoming therapy resistance in GBM$325,989
R01 · FY2013 · CA · contact PI
Protocal Specific Research Support$301,861
P30 · FY2013 · CA · contact PI
Overcoming Therapy Resistance in Glioblastoma$244,389
P50 · FY2013 · CA · contact PI
Influence of Anti-Angiogenic Therapy on Drug Delivery to Brain Tumors$48,893
R01 · FY2013 · NS
Influence of Anti-Angiogenic Therapy on Drug Delivery to Brain Tumors$540,310
R01 · FY2012 · NS
Animal Core$385,074
P50 · FY2012 · CA · contact PI
Epigenetic regulation of temozolomide responsiveness in glioblastoma$372,669
R01 · FY2012 · CA · contact PI
Overcoming therapy resistance in GBM$348,418
R01 · FY2012 · CA · contact PI
Protocal Specific Research Support$280,869
P30 · FY2012 · CA · contact PI
Overcoming Therapy Resistance in Glioblastoma$263,475
P50 · FY2012 · CA · contact PI
Overcoming therapy resistance in GBM$359,576
R01 · FY2011 · CA · contact PI
Epigenetic regulation of temozolomide responsiveness in glioblastoma$340,289
R01 · FY2011 · CA · contact PI
Protocal Specific Research Support$310,479
P30 · FY2011 · CA · contact PI
Overcoming therapy resistance in GBM$372,469
R01 · FY2010 · CA · contact PI
Epigenetic regulation of temozolomide responsiveness in glioblastoma$371,002
R01 · FY2010 · CA · contact PI
Protocal Specific Research Support$328,213
P30 · FY2010 · CA · contact PI
Epigenetic regulation of temozolomide responsiveness in glioblastoma$417,073
R01 · FY2009 · CA · contact PI
Overcoming therapy resistance in GBM$355,676
R01 · FY2009 · CA · contact PI
Protocal Specific Research Support$324,035
P30 · FY2009 · CA · contact PI
Epigenetic regulation of temozolomide responsiveness in glioblastoma$413,695
R01 · FY2008 · CA · contact PI
Early prediction of response to combined modality therapy by functional imaging$255,450
R21 · FY2008 · CA · contact PI
Optimizing EGFR inhibitor-based therapies in GBM$179,531
P50 · FY2008 · CA · contact PI
Early prediction of response to combined modality therapy by functional imaging$256,372
R21 · FY2007 · CA · contact PI
Optimizing EGFR inhibitor-based therapies in GBM$198,476
P50 · FY2007 · CA · contact PI
Optimizing EGFR inhibitor-based therapies in GBM$129,052
P50 · FY2006 · CA · contact PI
FLT PET imaging for evaluating molecular therapeutics$165,938
R21 · FY2005 · CA
Optimizing EGFR inhibitor-based therapies in GBM$144,642
P50 · FY2005 · CA
DAILY ORAL SIROLIMUS (RAPA) AND CISPLATIN WITH CONCURRENT THORACIC RADIATION$1,422
M01 · FY2005 · RR
FLT PET imaging for evaluating molecular therapeutics$165,938
R21 · FY2004 · CA
Optimizing EGFR inhibitor-based therapies in GBM$149,271
P50 · FY2004 · CA
ATM KINASE AS A NOVEL TARGET FOR RADIOSENSITIZING AGENTS$125,418
K08 · FY2003 · CA
ATM KINASE AS A NOVEL TARGET FOR RADIOSENSITIZING AGENTS$125,418
K08 · FY2002 · CA
ATM KINASE AS A NOVEL TARGET FOR RADIOSENSITIZING AGENTS$125,418
K08 · FY2001 · CA
ATM KINASE AS A NOVEL TARGET FOR RADIOSENSITIZING AGENTS$125,418
K08 · FY2000 · CA